Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091)
Background - In an international randomised controlled phase II study of temozolomide (TMZ) versus TMZ in combination with bevacizumab (BEV) in locally diagnosed non-1p/19q co-deleted World Health Organization grade 2 or 3 gliomas with a first and contrast-enhancing recurrence after initial radiothe...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
September 2023
|
| In: |
European journal of cancer
Year: 2023, Volume: 190, Pages: 1-15 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2023.112946 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ejca.2023.112946 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804923002988 
|
| Author Notes: | Jaap C. Reijneveld, Abigirl Machingura, Corneel Coens, Martin J. B. Taphoorn, Walter Taal, Paul M. Clement, Ahmed Idbaih, Filip Y. F. de Vos, Martin Klein, Wolfgang Wick, Paul J. Mulholland, Joanne Lewis, Vassilis Golfinopoulos, Irina Ghislain, Andrew Bottomley, Martin J. van den Bent, on behalf of the EORTC Brain Tumor Group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1861514581 | ||
| 003 | DE-627 | ||
| 005 | 20240329080824.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231011s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2023.112946 |2 doi | |
| 035 | |a (DE-627)1861514581 | ||
| 035 | |a (DE-599)KXP1861514581 | ||
| 035 | |a (OCoLC)1425210755 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Reijneveld, Jaap C. |e VerfasserIn |0 (DE-588)1243671963 |0 (DE-627)1774659212 |4 aut | |
| 245 | 1 | 0 | |a Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091) |c Jaap C. Reijneveld, Abigirl Machingura, Corneel Coens, Martin J. B. Taphoorn, Walter Taal, Paul M. Clement, Ahmed Idbaih, Filip Y. F. de Vos, Martin Klein, Wolfgang Wick, Paul J. Mulholland, Joanne Lewis, Vassilis Golfinopoulos, Irina Ghislain, Andrew Bottomley, Martin J. van den Bent, on behalf of the EORTC Brain Tumor Group |
| 264 | 1 | |c September 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 19. Juni 2023, Artikelversion: 13. Juli 2023 | ||
| 500 | |a Gesehen am 11.10.2023 | ||
| 520 | |a Background - In an international randomised controlled phase II study of temozolomide (TMZ) versus TMZ in combination with bevacizumab (BEV) in locally diagnosed non-1p/19q co-deleted World Health Organization grade 2 or 3 gliomas with a first and contrast-enhancing recurrence after initial radiotherapy, and overall survival at 12 months was not significantly different (61% in the TMZ arm and 55% in the TMZ + BEV arm). - Objectives - Health-related quality of life (HRQoL) was a key secondary end-point in this trial, and the main objective of this study was to determine the impact of the addition of BEV to TMZ on HRQoL. - Methods - HRQoL was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30 (version 3) and QLQ-BN20 at baseline, and then every 12 weeks until disease progression. The pre-selected primary HRQoL end-point was the QLQ-C30 global health scale, with self-perceived cognitive functioning and pain selected as secondary HRQoL issues. Analysis was undertaken using linear mixed modelling and complemented with sensitivity analyses using summary statistics. A difference was considered clinically relevant with ≥10 points difference on a 100-point scale. - Results - Baseline compliance was high at 94% and remained above 60% until 72 weeks, limiting the analysis to 60 weeks. Compliance was similar in both arms. We found no statistically significant or clinically significant differences between the primary HRQoL end-point in both treatment arms (p = 0.2642). The sensitivity analyses confirmed this finding. The overall test for post-baseline differences between the two treatment arms also showed no statistically or clinically significant differences regarding the selected secondary end-point scales. - Interpretation - The addition of BEV to TMZ in this patient group neither improves nor negatively impacts HRQoL. | ||
| 650 | 4 | |a Bevacizumab | |
| 650 | 4 | |a EORTC | |
| 650 | 4 | |a Glioma | |
| 650 | 4 | |a Health-related quality of life | |
| 650 | 4 | |a RCTs | |
| 650 | 4 | |a Temozolomide | |
| 700 | 1 | |a Machingura, Abigirl |e VerfasserIn |4 aut | |
| 700 | 1 | |a Coens, Corneel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Taphoorn, Martin J. B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Taal, Walter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Clement, Paul M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Idbaih, Ahmed |e VerfasserIn |4 aut | |
| 700 | 1 | |a de Vos, Filip Y. F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Klein, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wick, Wolfgang |d 1970- |e VerfasserIn |0 (DE-588)120297736 |0 (DE-627)080586929 |0 (DE-576)186221320 |4 aut | |
| 700 | 1 | |a Mulholland, Paul J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lewis, Joanne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Golfinopoulos, Vassilis |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ghislain, Irina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bottomley, Andrew |e VerfasserIn |4 aut | |
| 700 | 1 | |a van den Bent, Martin J. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 190(2023) vom: Sept., Artikel-ID 112946, Seite 1-15 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091) |
| 773 | 1 | 8 | |g volume:190 |g year:2023 |g month:09 |g elocationid:112946 |g pages:1-15 |g extent:15 |a Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091) |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2023.112946 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804923002988 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20231011 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 120297736 |a Wick, Wolfgang |m 120297736:Wick, Wolfgang |d 910000 |d 911100 |e 910000PW120297736 |e 911100PW120297736 |k 0/910000/ |k 1/910000/911100/ |p 10 | ||
| 999 | |a KXP-PPN1861514581 |e 4383905919 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Jaap C. Reijneveld, Abigirl Machingura, Corneel Coens, Martin J. B. Taphoorn, Walter Taal, Paul M. Clement, Ahmed Idbaih, Filip Y. F. de Vos, Martin Klein, Wolfgang Wick, Paul J. Mulholland, Joanne Lewis, Vassilis Golfinopoulos, Irina Ghislain, Andrew Bottomley, Martin J. van den Bent, on behalf of the EORTC Brain Tumor Group"]},"id":{"doi":["10.1016/j.ejca.2023.112946"],"eki":["1861514581"]},"relHost":[{"origin":[{"dateIssuedKey":"1992","dateIssuedDisp":"1992-","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","publisher":"Elsevier ; Pergamon Press"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"recId":"266883400","disp":"Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091)European journal of cancer","corporate":[{"role":"isb","display":"European Organization for Research on Treatment of Cancer"},{"role":"isb","display":"European Association for Cancer Research"},{"role":"isb","display":"European School of Oncology"}],"titleAlt":[{"title":"EJC online"}],"pubHistory":["28.1992 -"],"id":{"eki":["266883400"],"issn":["1879-0852"],"zdb":["1468190-0"]},"part":{"text":"190(2023) vom: Sept., Artikel-ID 112946, Seite 1-15","volume":"190","extent":"15","pages":"1-15","year":"2023"}}],"person":[{"display":"Reijneveld, Jaap C.","role":"aut","given":"Jaap C.","family":"Reijneveld"},{"display":"Machingura, Abigirl","given":"Abigirl","role":"aut","family":"Machingura"},{"family":"Coens","role":"aut","given":"Corneel","display":"Coens, Corneel"},{"display":"Taphoorn, Martin J. B.","role":"aut","given":"Martin J. B.","family":"Taphoorn"},{"family":"Taal","role":"aut","given":"Walter","display":"Taal, Walter"},{"display":"Clement, Paul M.","family":"Clement","given":"Paul M.","role":"aut"},{"display":"Idbaih, Ahmed","family":"Idbaih","given":"Ahmed","role":"aut"},{"display":"de Vos, Filip Y. F.","family":"de Vos","given":"Filip Y. F.","role":"aut"},{"family":"Klein","given":"Martin","role":"aut","display":"Klein, Martin"},{"display":"Wick, Wolfgang","family":"Wick","role":"aut","given":"Wolfgang"},{"display":"Mulholland, Paul J.","role":"aut","given":"Paul J.","family":"Mulholland"},{"given":"Joanne","role":"aut","family":"Lewis","display":"Lewis, Joanne"},{"role":"aut","given":"Vassilis","family":"Golfinopoulos","display":"Golfinopoulos, Vassilis"},{"display":"Ghislain, Irina","family":"Ghislain","role":"aut","given":"Irina"},{"family":"Bottomley","role":"aut","given":"Andrew","display":"Bottomley, Andrew"},{"given":"Martin J.","role":"aut","family":"van den Bent","display":"van den Bent, Martin J."}],"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"September 2023"}],"title":[{"title_sort":"Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091)","title":"Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091)"}],"note":["Online verfügbar: 19. Juni 2023, Artikelversion: 13. Juli 2023","Gesehen am 11.10.2023"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1861514581","physDesc":[{"noteIll":"Illustrationen","extent":"15 S."}]} | ||
| SRT | |a REIJNEVELDHEALTHRELA2023 | ||